An interventional study of Ketamine Hydrochloride and Dexmedetomidine Hydrochloride in Postoperative Pain and Opioid Use, sponsored by Ciusss de L'Est de l'Île de Montréal. Terminated at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Ciusss de L'Est de l'Île de Montréal · Not applicable, Interventional, and Prevention
Not enough funding. recruitment less than anticipated
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies testing ketamine in Pain, Postoperative — 9 open to participants now, 11 under way, 3 of them phase 3. Ketamine · Pain, Postoperative.
Among the 92 studies testing ketamine in Pain, Postoperative, this one is the 76th largest by enrollment, is one of 3 that started in 2018, is one of 17 with no phase, and was the 51st registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →9 of the 92 studies testing ketamine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Texas Tech University Health Sciences Center · Sites in United States
Ages 18–65
Fatima Memorial Hospital · Sites in Pakistan
Ages 18–50 · Women only
Universidad de Antioquia · Sites in Colombia
Ages 18+ · Healthy volunteers
University of Oklahoma · Sites in United States
Ages 18–100
Assiut University
Ages 18–60
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 16 · Phase 3 19 · Phase 4 42
First in 2001; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 78 across the 92 interventional studies. Of the 65 that completed or were terminated, 17 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 92 has an industry lead sponsor. The 10 most frequent:
Ciusss de L'Est de l'Île de Montréal is the lead sponsor of 90 studies on the registry; 32 are open to participants now.
Ciusss de L'Est de l'Île de Montréal has 7 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
7 of the studies testing ketamine in Pain, Postoperative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07370181Phase 3Assiut UniversityKetamine Irrigation Analgesia in Laparoscopic Cholecystectomy | 2027-02-01 |
| NCT07197684Aga Khan UniversityUltrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery | 2026-12-01 |
| NCT04248205University of OklahomaKetamine for Post-operative Analgesia in Hemorrhoidectomy | 2027-01 |
| NCT06738043Tanta UniversityDexmedetomidine Versus Ketamine as Adjuvants in Bariatric Surgery | 2027-04-20 |
| NCT06903819Texas Tech University Health Sciences CenterKetamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 92 studies testing ketamine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative pain after VATS surgery is significant and associated with moderate to high post operative morphine requirements, which can cause opioid related side effects and delay postoperative recovery. To reduce this requirement, multimodal analgesia with non opioid medication such as dexmedetomidine and ketamine can be used. These drugs have demonstrated significant opioid-sparing properties after various types of surgeries. However, very little is known about their ability to do so in VATS surgery. Also, their relative opioid-sparing properties have not been compared, and it is not known whether their combined use can lead to an additional opioid-sparing effect. The primary goal of this study will be to determine the impact of a combined intra operative infusion of ketamine and dexmedetomidine on postoperative morphine requirements in patients undergoing elective VATS, compared to both these drugs infused separately.
The hypothesis is that this combined infusion will lead to a 30% further reduction in morphine requirements, 24h after surgery, compared to both these drugs infused separately.
Video-assisted thoracic surgery (VATS) for pulmonary resection is associated with less tissue trauma, less impairment in lung function, and reduced postoperative pain compared with thoracotomy, although many patients continue to report significant acute postoperative pain. If not well-controlled, postoperative thoracic pain can lead to splinting and inadequate recovery of pulmonary function.
Enhancing the quality of postoperative analgesia while reducing intra and postoperative opioid requirements is an important issue that has been one of the main focus of Enhanced Recovery After Surgery (ERAS) protocols. Indeed, the key factors that delay postoperative recovery include parenteral opioids and bed rest and immobility secondary to postoperative pain. While opioids are effective at treating even severe pain, their use is associated with dose-related adverse effects such as respiratory depression, sedation, postoperative nausea and vomiting, urinary retention, ileus, opioid-induced hyperalgesia and chronic postoperative pain. More importantly, opioids depress host immunity and neuroendocrine function and may negatively affect cancer recurrence and survival after lung cancer surgery.
Hence, given the importance of good postoperative analgesia and the significance of opioid-related adverse effects, the reduction of opioid requirements and postoperative pain through multimodal analgesia is an important matter. Focusing on this goal, the ERAS protocols have shown great efficacy in improving patient's care after colorectal surgery and they are now being applied to pancreatic, ENT, bariatric, urologic and many more major surgeries.
It is probably only a matter of time before ERAS protocols are applied to VATS surgery; however, the optimal way of providing postoperative analgesia after VATS has not yet been determined, unlike colorectal surgery. Indeed, thoracic epidural analgesia, single-shot and continuous paravertebral and intercostal nerve blocks and patient-controlled intravenous analgesia have all been evaluated, and none of these has consistently emerged as being superior to the others or to intravenous analgesia. Thoracic epidural analgesia provides effective pain control for thoracotomy but its benefits following thoracoscopy are not uniform. Furthermore, the risks of sympathectomy-induced hypotension and neurologic injury from epidural hematoma may not be justified considering the lesser postoperative pain and impairment in pulmonary function compared to thoracotomy. Continuous paravertebral blocks are an effective alternative to epidural analgesia although their performance may be challenging and time consuming, and catheters may be difficult to thread or get accidentally removed, leading to block failure. Furthermore, as for epidural analgesia, paravertebral catheter placement is contra-indicated in patients with impaired coagulation and/or infection. Single-shot intercostal and paravertebral blocks are less invasive although their benefit is restricted to the first twelve postoperative hours.
Moreover, none of these regional anesthesia techniques can treat the ipsilateral shoulder pain that is often associated with VATS, and opioid analgesia might still be required.
An intravenous opioid patient-controlled analgesia combined to multimodal analgesia with acetaminophen and non-steroidal anti-inflammatoy drug (NSAID) is commonly used in many institutions and has shown to provide adequate and effective postoperative analgesia. However, significant acute postoperative pain and moderate to high opioid consumption are still reported after VATS. There is definitely some place for improvement, which could come from other non-opioid analgesic adjuncts such as ketamine and/or dexmedetomidine.
Ketamine is an anesthetic drug that has well-known analgesic properties due to its ability to block NMDA receptors. An intraoperative bolus followed with a low-dose infusion reduces postoperative opioid requirements by 30-40%, without causing significant side effects. Similarly, dexmedetomidine is a centrally acting α2-agonist with sedating and analgesic properties. When used intra-operatively, it significantly reduces hypnotics and opioids requirements, decreases median pain scores and reduces postoperative morphine consumption by approximately 30%. These systematic reviews seem to indicate a greater morphine-sparing effect from ketamine compared to dexmedetomidine although this has not been evaluated thoroughly. Indeed, only one study compared ketamine's morphine-sparing effects to that of dexmedetomidine, in patients undergoing spine surgery. Both infusions were started postoperatively and provided significant morphine sparing effects compared to placebo. Ketamine's morphine-sparing effect appeared greater than that of dexmedetomidine, although this was not statistically significant, as this study was not powered for that outcome. Hence, their morphine-sparing effect might be different but this difference is likely small. Their impact on postoperative opioid requirement after VATS surgery has not been studied, even though it could be highly beneficial, not only for the reduction of postoperative opioid requirements but for the reduction of chronic postoperative pain.
Another interesting reason for using these analgesic adjuvants for intra operative analgesia is their ability to prevent chronic post operative pain.
More interesting would be to investigate whether their combined use leads to greater morphine-sparing effect. Indeed, although their combination for paediatric procedural sedation is well described, the impact of a combined dexmedetomidine-ketamine intraoperative infusion on postoperative analgesia and opioid requirements has not been evaluated.
Study outcome and hypothesis
The primary goal of this study will be to determine the impact of a combined intra operative infusion of ketamine and dexmedetomidine on postoperative morphine requirements in patients undergoing elective VATS, compared to both these drugs infused separately.
The hypothesis is that this combined infusion will lead to a 30% further reduction in morphine requirements, 24h after surgery, compared to both these drugs infused separately.
Secondary outcomes will be to evaluate the impact of a combined dexmedetomidine-ketamine infusion on:
METHODOLOGY
Study design
This will be a prospective, randomized, double blind study.
Population
Patients undergoing elective VATS and receiving an opioid intravenous patient-controlled analgesia (PCA) combined with acetaminophen and NSAID for postoperative analgesia.
Duration of study
1 year
Sample size Postoperative cumulative morphine consumption 24h after surgery in our institution has been determined by reviewing the files of 50 patients who underwent VATS surgery and received a PCA combined to acetaminophen and NSAID for postoperative analgesia. These patients used an average (standard deviation (SD)) of 39.5 (17.3) mg of morphine.
Considering an opioid-sparing effect of 30% from dexmedetomidine and ketamine alone, a mean morphine consumption of 27.7(11) mg can be expected in the ketamine and dexmedetomidine groups.
A 30% further reduction in opioid requirement from combining ketamine to dexmedetomidine will be considered significant.
Thus, a sample size of 37 patients per group would give us 80% power to detect such a difference, alpha 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
Drug: Ketamine Hydrochloride
Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
Drug: Dexmedetomidine Hydrochloride
Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
Combination Product: dexmedetomidine Hydrochloride and Ketamine Hydrochloride
Intraoperative bolus and infusion (see arm description)
Also known as: ketamine
Intraoperative bolus and infusion (see arm description)
Also known as: dexmedetomidine
Drug pages: DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · KetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Intraoperative bolus and infusion (see arm description)
Also known as: dexmedetomidine and ketamine
Day 1 Postoperative morphine requirement
Cumulative dose of morphine used by the patient
Time frame: Day 1
day 2 Postoperativve morphine requirement
cumulative dose of morphine used by the patient
Time frame: day 2
Pain score at rest 24h
Pain score (Verbal Numeric Scale (0-10) at rest
Time frame: day 1
Pain score at rest 48h
Pain score (Verbal Numeric Scale (0-10) at rest
Time frame: day 2
Pain score at cough 24h
Pain score (Verbal Numeric Scale (0-10) at cough
Time frame: day 1
Pain score at cough 48h
Pain score (Verbal Numeric Scale (0-10) at cough
Time frame: day 2
intraoperative fentanyl requirement
intraoperative dose of fentanyl used to treat intraoperative pain
Time frame: for incision to wound closure
chest tube removal
time (days) for chest tube removal after surgery
Time frame: 1 week
chronic postoperative pain
patients reporting persistent post operative pain
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in Dec 2025, 94 months.
How these figures are worked out, and which studies are left out of them.
Not enough funding. recruitment less than anticipated
Not enough funding. recruitment less than anticipated
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketamine · Dexmedetomidine
Ciusss de L'Est de l'Île de Montréal